N

Nashville Neuroscience Group | Bryant Research Group

Research site

(Unclaimed)

Location

2004 Hayes Street, Suite 650, Nashville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Atogepant

ABP-450

Erenumab

Sumatriptan

AMG334

LY2951742

Rimegepant

NXN-462

AGN-241689

Lasmiditan

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 18 total trials

Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine...

Invitation-only

Migraine

Drug: ABP-450

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per m...

Active, not recruiting

Migraine

Drug: ABP-450

Drug: Placebo

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting

Episodic Migraine

Drug: Placebo

Drug: BOTOX

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light a...

Enrolling

Chronic Migraine

Drug: Atogepant